NEOS THERAPEUTICS,INC. (NASDAQ:NEOS) Files An 8-K Other Events
Item 8.01. Other Events.
On December20, 2016, Neos Therapeutics,Inc. issued a press
release entitled Neos Therapeutics Completes Resubmission of NDA
for Cotempla XR-ODT for the Treatment of ADHD (the Press
Release). A copy of the Press Release is filed herewith as
Exhibit99.1 and is incorporated herein by reference.
Item 9.01. Financial Statements and Exhibits.
(d)Exhibits:
|
Exhibit No. |
|
Description |
|
99.1 |
Press release dated December20, 2016 |
About NEOS THERAPEUTICS, INC. (NASDAQ:NEOS)
Neos Therapeutics, Inc. is a pharmaceutical company. The Company is focused on developing, manufacturing and commercializing products utilizing its modified-release drug delivery technology platform. Its segment is engaged in the development, manufacturing and commercialization of pharmaceuticals. It has utilized its platform to develop its product for the treatment of attention deficit hyperactivity disorder (ADHD). Its product candidates are extended-release (XR), medications in patient-friendly, orally disintegrating tablets (ODT) or liquid suspension dosage forms. Its branded product and product candidates incorporate over two of the prescribed medications for the treatment of ADHD, methylphenidate and amphetamine. Its modified-release drug delivery platform has enabled it to create extended-release ODT and liquid suspension dosage forms of the medications. It focuses on developing Adzenys XR-ODT, Cotempla XR-ODT and NT-0201. NEOS THERAPEUTICS, INC. (NASDAQ:NEOS) Recent Trading Information
NEOS THERAPEUTICS, INC. (NASDAQ:NEOS) closed its last trading session down -0.20 at 6.60 with 102,500 shares trading hands.
